Quince Therapeutics (QNCX) News Today $1.66 -0.06 (-3.49%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of "Buy" from AnalystsQuince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) has earned an average rating of "Buy" from the five analysts that are currently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the compaJanuary 2, 2025 | marketbeat.comQuince Therapeutics' (QNCX) "Buy" Rating Reiterated at D. Boral CapitalD. Boral Capital reiterated a "buy" rating and issued a $12.00 target price on shares of Quince Therapeutics in a report on Thursday.January 2, 2025 | marketbeat.comBrookline Capital Management Predicts QNCX FY2024 EarningsQuince Therapeutics, Inc. (NASDAQ:QNCX - Free Report) - Research analysts at Brookline Capital Management issued their FY2024 earnings estimates for shares of Quince Therapeutics in a research note issued to investors on Wednesday, December 18th. Brookline Capital Management analyst K. Raja forecDecember 20, 2024 | marketbeat.comQuince Therapeutics initiated with a Buy at BrooklineDecember 19, 2024 | msn.comBrookline Capital Initiates Coverage of Quince Therapeutics (QNCX) with Buy RecommendationDecember 19, 2024 | msn.comBrookline Capital Management Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX)Brookline Capital Management started coverage on shares of Quince Therapeutics in a research note on Wednesday. They set a "buy" rating and a $9.00 price objective for the company.December 18, 2024 | marketbeat.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Sees Large Increase in Short InterestQuince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) saw a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 2,170,000 shares, a growth of 21.2% from the November 15th total of 1,790,000 shares. Currently, 6.7% of the shares of the company are short sold. Based on an average daily trading volume, of 548,900 shares, the days-to-cover ratio is presently 4.0 days.December 16, 2024 | marketbeat.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest UpdateQuince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) was the target of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 1,790,000 shares, a decrease of 23.8% from the October 31st total of 2,350,000 shares. Based on an average daily volume of 527,400 shares, the days-to-cover ratio is currently 3.4 days. Approximately 5.5% of the shares of the company are short sold.November 29, 2024 | marketbeat.comQuince Therapeutics Share Price (QNCX.US)November 18, 2024 | lse.co.ukShort Interest in Quince Therapeutics, Inc. (NASDAQ:QNCX) Increases By 23.0%Quince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 2,350,000 shares, an increase of 23.0% from the October 15th total of 1,910,000 shares. Based on an average trading volume of 554,300 shares, the days-to-cover ratio is presently 4.2 days. Approximately 7.3% of the company's stock are sold short.November 15, 2024 | marketbeat.comQuince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | businesswire.comQuince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia ResearchNovember 13, 2024 | finance.yahoo.comQuince Therapeutics presents safety data from ATTeST trial at CNS meetingNovember 13, 2024 | markets.businessinsider.comQuince Therapeutics presents data from prior Phase 3 ATTeST clinical trialNovember 13, 2024 | markets.businessinsider.comQuince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual MeetingNovember 11, 2024 | businesswire.comQuince Therapeutics initiated with a Buy at MaximNovember 8, 2024 | markets.businessinsider.comMaxim Group Initiates Coverage of Quince Therapeutics (QNCX) with Buy RecommendationNovember 8, 2024 | msn.comMaxim Group Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX)Maxim Group initiated coverage on shares of Quince Therapeutics in a research report on Thursday. They issued a "buy" rating and a $6.00 price objective for the company.November 7, 2024 | marketbeat.comQuince Therapeutics initiated with a Buy at Rodman & RenshawOctober 30, 2024 | markets.businessinsider.comQuince Therapeutics (NASDAQ:QNCX) Upgraded at RODMAN&RENSHAWRODMAN&RENSHAW raised shares of Quince Therapeutics to a "strong-buy" rating in a research note on Tuesday.October 30, 2024 | marketbeat.comRodman & Renshaw Initiates Coverage of Quince Therapeutics (QNCX) with Buy RecommendationOctober 30, 2024 | msn.comEF Hutton Initiates Coverage of Quince Therapeutics (QNCX) with Buy RecommendationOctober 22, 2024 | msn.comQuince Therapeutics to Participate at Upcoming Investor ConferencesOctober 14, 2024 | businesswire.comQuince Therapeutics, Inc. (NASDAQ:QNCX) CEO Dirk Thye Purchases 77,500 SharesSeptember 4, 2024 | insidertrades.comQuince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | finance.yahoo.comQNCX Quince Therapeutics, Inc.August 30, 2024 | seekingalpha.comQuince Therapeutics, Inc. (NASDAQ:QNCX) President Charles S. Ryan Acquires 48,387 SharesAugust 23, 2024 | insidertrades.comQuince Therapeutics, Inc. (NASDAQ:QNCX) COO Brendan Hannah Acquires 30,845 SharesAugust 22, 2024 | insidertrades.comQuince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDexAugust 20, 2024 | seekingalpha.comQuince reports data from Phase III Ataxia-Telangiectasia treatment trialAugust 17, 2024 | finance.yahoo.comQNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024August 13, 2024 | investorplace.comQuince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial ResultsAugust 13, 2024 | stockhouse.comQuince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-TelangiectasiaJune 25, 2024 | businesswire.comQuince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex SystemJune 3, 2024 | businesswire.comQNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024May 13, 2024 | investorplace.comQuince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 13, 2024 | businesswire.comQuince Therapeutics to Present at The Citizens JMP Life Sciences ConferenceMay 6, 2024 | businesswire.comQuince Therapeutics, Inc. (QNCX)April 25, 2024 | finance.yahoo.comQNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023April 2, 2024 | investorplace.comQuince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial ResultsApril 1, 2024 | finance.yahoo.comQuince Therapeutics Launches Scientific Advisory BoardFebruary 22, 2024 | finance.yahoo.comQuince Therapeutics Launches Scientific Advisory BoardFebruary 22, 2024 | businesswire.comQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of DirectorsFebruary 15, 2024 | finance.yahoo.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Sees Significant Drop in Short InterestQuince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 1,900,000 shares, a decrease of 7.3% from the January 15th total of 2,050,000 shares. Currently, 6.0% of the company's shares are sold short. Based on an average trading volume of 91,100 shares, the days-to-cover ratio is presently 20.9 days.February 15, 2024 | marketbeat.comQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of DirectorsFebruary 15, 2024 | businesswire.comQuince Therapeutics (NASDAQ:QNCX) Stock Price Down 8.5%Quince Therapeutics (NASDAQ:QNCX) Stock Price Down 8.5%February 14, 2024 | marketbeat.comQuince Therapeutics to Participate at Investor Events in January 2024January 4, 2024 | finance.yahoo.comQuince Therapeutics Inc QNCXNovember 11, 2023 | morningstar.comChief Business Officer and COO at Quince Therapeutics Acquires Company Stock Options Worth 75,000 SharesOctober 27, 2023 | benzinga.comQuince Therapeutics Chief Scientific Officer Awarded $291K Worth of Stock OptionsOctober 25, 2023 | benzinga.com Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address QNCX Media Mentions By Week QNCX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QNCX News Sentiment▼0.000.46▲Average Medical News Sentiment QNCX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QNCX Articles This Week▼01▲QNCX Articles Average Week Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Tango Therapeutics News Trevi Therapeutics News Chimerix News SNDL News biote News Voyager Therapeutics News iTeos Therapeutics News LifeVantage News Aquestive Therapeutics News Immutep News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QNCX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QNCX Stock Alerts